Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Mark G Kris Bob T. Li Giuseppe Giaccone |
| Publication date | April 21, 2015 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |